Personalized Medicine – Products

Tecan is announcing a streamlined solution portfolio to enable liquid biopsy applications, from upstream workflows to downstream analysis for genomics and proteomics applications.

The project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial. The Assay will be available as a service in the Babraham Institute’s Flow Cytometry Facility.

Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease.

PlaqueTec announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Oligonucleotide therapeutics (OTs) show great promise in the field of personalized medicine as a method of targeting undruggable proteins.

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.

ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies.

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms.